Shijiazhuang Yiling Pharmaceutical Co Ltd

The company maintains a strong capital structure, with total equity of CNY 10.99 billion and total liabilities of CNY 2.69 billion, resulting in a debt-to-equity ratio of 0.0. Its liquidity position is characterized by a current ratio of 2.36, indicating a moderate ability to meet short-term obligations. Free cash flow of CNY 1.16 billion and operating cash flow of CNY 1.78 billion suggest robust cash generation, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity (ROE) of 11.71% and a return on assets (ROA) of 9.41%, both exceeding the typical thresholds for the pharmaceutical industry. Gross profit of CNY 4.96 billion and operating income of CNY 1.62 billion reflect strong cost control and pricing power. However, the company’s net income of CNY 1.29 billion is lower than gross profit, indicating some pressure from operating expenses. Geographic and segment exposure is not explicitly detailed in the available data, but the company’s revenue of CNY 7.83 billion is likely concentrated in China, as disclosed in its primary market. No material revenue diversification across regions or product lines is reported. The company’s growth trajectory is supported by a strong cash flow position and a low dilution risk, with no near-term pressure from share issuance. Capital expenditures of CNY -245.6 million suggest a focus on cost efficiency rather than expansion. Analysts project a mean price target of CNY 19.09, with a strong-buy recommendation from two analysts. Risk factors include a medium liquidity risk due to the current ratio and a negative net cash position after debt. The company has a low dilution potential, with no significant dilution sources identified in the latest filings. Recent events include the publication of the latest financial report, which highlights the company’s strong cash flow and profitability. No major regulatory or geopolitical risks are currently flagged, though the pharmaceutical industry remains subject to policy changes in China.